The first potent and selective sGC stimulator was riociguat which effectively enhances cGMP production; riociguat has been approved in 2013 for the treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). This evidence concerns the gene SGCB and chronic thromboembolic pulmonary hypertension.